submit to the journals

Videos

As well as peer-reviewed journals, touchONCOLOGY also provide video interviews, procedures and general updates on the latest trends within the area, as well as featuring carefully selected video from our partners.
Arnon P Kater, EHA 2018 – TP53 mutations in relapsed/refractory CLL – the MURANO trial
touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab. 1. Why do chronic lymphocytic...
Annalisa Chiappella, EHA 2018 – TP53 mutations in DLBCL: the FIL-DLCL04 study
Annalisa Chiapella from Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Italy talks to touchONCOLOGY about patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation, and the aims and findings of the FIL-DLCL04 study to help tackle this. 1...
Martin Hutchings, EHA 2018 – ECHELON-1 trial and chemotherapy regimens in Hodgkin’s lymphoma
Martin Hutchings from Copenhagen University Hospital discusses the ECHELON-1 trial and treatment strategies in Hodgkin's lymphoma. 1. What are the limitations of current ABVD chemotherapy regimes for advanced Hodgkin’s lymphoma? (0:10) 2. Could you tell us a little about the ECHELON-1...
Paul Richardson, EHA 2018 – Combination therapy in multiple myeloma: the OPTIMISMM trial
Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma. 1. Why is there a need for new combinations of therapies in relapsed/...
Willem Fibbe, EHA 2018 – Therapeutic potential of mesenchymal stromal cells
We catch up with editorial board member Willem Fibbe from Leiden University Medical Centre to discuss mesenchymal stromal cells and their therapeutic potential in the clinic. 1. What properties of mesenchymal stromal cells (MSCs) have led to the investigation of their therapeutic...
Muzaffar Qazilbash, EHA 2018 – Busulfan + melphalan in high-risk multiple myeloma
Muzaffar Qazilbash from The University of Texas MD Anderson Cancer Center talks to touchONCOLOGY about investigating busulfan plus melphalan as a potential combination therapy for high-risk multiple myeloma. 1. What was the rationale for using a combined busulfan and melphalan...
Lori J Wirth, ASCO 2018 – Treatment approaches and advances in thyroid research
touchONCOLOGY meets with Lori J Wirth from Harvard Medical School and Massachusetts General Hospital in Boston, MA to discuss important treatment approaches and advances for thyroid cancer, including investigating lenvatinib and major findings of the SELECT trial, and how the clinical...
Giuseppe Procopio, ASCO 2018 – Sorafenib in renal cell carcinoma - the RESORT trial
Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases. 1. What is the rationale for...
John L Marshall, ASCO 2018 – PARP inhibitors for the personalized treatment of colorectal cancer
Editorial board member John L Marsahll from The Ruesch Center for the Cure of GI Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center in Washington, DC discusses unmet needs and major advances in the treatment of colorectal cancers, and how PARP inhibitors may...
Ian W Flinn, ASCO 2018 – Recent advances in relapsed/refractory CLL, DLBCL & follicular lymphoma
Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma. 1. What are the most important unmet needs...
Jeffrey S Weber, ASCO 2018 – Resected stage III melanoma and the CheckMate 238 trial
touchONCOLOGY talks to Jeffrey S Weber from the Laura and Isaac Perlmutter Cancer Cente and NYU Langone Medical Center about the limitations of ipilimumab for the treatment of resected stage III melanoma and how the findings of the CheckMate238 trial can improve the safety profile of this...
Arnaud Méjean, ASCO 2018 – Cytoreductive nephrectomy and the CARMENA trial
Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial. 1. What is...
Shaji Kumar, ASCO 2018 – Advances in treatment approaches and guidelines for multiple myeloma
We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as important updates in the latest NCCN guidelines. 1. What do you consider the most important unmet needs in the treatment of multiple myeloma? (0:11) 2. What...
Eleni Andreopoulou, ASCO 2018 – Improving quality of life in patients with breast cancer
Editorial board member, Eleni Andreopoulou, discusses interventions to improve the quality of life of patients with breast cancer throughout their treatment. Q. What personalized interventions improve the quality of life of breast cancer patients during and after chemotherapy treatment? (0:...
Eleni Andreopoulou, ASCO 2018 – Advances in molecular therapy in triple-negative breast cancer
Editorial board member, Eleni Andreopoulou, from Weill Cornell Medical College in New York, US, discusses molecular subtyping and advances in molecularly-targeted therapy in triple-negative breast cancer. Q1. What are the major challenges of treating triple-negative breast cancer? (0:11) Q2...

Out Now